Daewoong develops drug candidate for oral obesity treatment
Daewoong Pharmaceutical announced Tuesday that it has filed for a domestic patent for a new obesity drug that suppresses ...
pulmonologyadvisor3d
GLP-1 Drug Shortages: How Do They Affect Patients With Diabetes?
GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...
TCTMD6d
Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key
In addition, in the coming years, oral GLP-1 receptor agonists and injectable formulations that require less-frequent ...
Yahoo5d
The Woman’s World Expert-Reviewed Glossary of GLP-1, Semaglutide and Telehealth
Depending on the medication, the effects can last for a minimum of 24 hours to a few weeks. Examples include dulaglutide, ...
BioSpace5d
Fledgling Obesity Biotech Metsera Raises Another $215M for Long-Acting GLP-1
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...
T-Net2d
Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Ethics Board Approval Granted for Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in ...
Lexaria Bioscience Corp.: Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global i ...
PharmiWeb4d
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the ...
Morningstar6d
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
All drugs will be administered daily by oral tablet or capsule - there are ... during a multi-week rodent study without the addition of any GLP-1 drugs. Lexaria is looking forward to discovering ...